Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

November 3, 2026

— Presentations to be webcast on www.exelixis.com —

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 3, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:

- Guggenheim 3rd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, November 10 in Boston.
- Stifel 2026 Healthcare Conference: Exelixis is scheduled to present at 1:20 p.m. ET / 10:20 a.m. PT on Wednesday, November 11 in New York City.
- UBS Global Biopharma Conference 2026: Exelixis is scheduled to present at 9:20 a.m. GMT / 4:20 a.m. ET / 1:20 a.m. PT on Tuesday, November 17 in London.
- 2026 Jefferies Global Healthcare Conference in London: Exelixis is scheduled to present at 1:30 p.m. GMT / 8:30 a.m. ET / 5:30 a.m. PT on Wednesday, November 18 in London.

To access the webcast links, log on to www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103186604/en/

Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com

Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcomllc.com

Source: Exelixis, Inc.